CELG News and Press, Celgene Corporation From 10/29/19

Company Overview Allogene Therapeutics ( ALLO ) is a clinical stage biotechnology company pioneering the development of allogeneic CAR T (“AlloCAR T”) therapies for cancer. Allogene believes that the next revolution in cancer treatment is the development of AlloCAR T therapie...

Bristol-Myers Squibb ( BMY ) is transforming itself into a more powerful biopharmaceutical company through the acquisition of Celgene ( CELG ). Although the stock gained about 21% since the merger was announced in January 2019, the valuation is still lower than many of the company's peers ...

For the most part, biotech stocks aren't having a great year with only a little over two months left in 2019. The top biotech-focused exchange-traded funds (ETFs) are trailing the S&P 500 year to date. But Geron (NASDAQ: GERN) and Celgene (NASDAQ: CELG) are sizzling hot, with the s...

Bristol-Myers Squibb (NYSE: BMY ) extends the expiration date of the offers to exchange notes issued by Celgene (NASDAQ: CELG ) for up to $19.85B aggregate principal amount of new notes to be issued by BMY to October 31. More news on: Bristol-Myers Squibb Company, Celgene Corporation, He...

Trade uncertainty is likely to remain an issue until improving trade relations between China and the United States results in a signed agreement, creating market opportunities for investors. There's no telling what stocks will pop the most, but our most recent research suggests dividend-payi...

(Source: imgflip) Dividend Kings runs four model portfolios to fulfill various needs of our members. Today I wanted to highlight Bristol-Myers ( BMY ), the 3rd biggest winner in our Deep Value portfolio and a company I own in my retirement portfolio (where I keep 100% of my life sav...

Wheelchair Accessible Balloon Lifts Off at Atlanta Area Festival The MS MindShift: A New View of MS initiative from Celgene Corporation (NASDAQ: CELG) and the Multiple Sclerosis Association of America (MSAA) is making its third stop at the Owl-O-Ween Hot Air Balloon Festival in K...

Allergan (NYSE: AGN ) resumed with Market Perform rating and $180 (7% upside) price target at Bernstein. More news on: Allergan plc, Amgen Inc., Biogen Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Biotech is in the doldrums. The SPDR S&P Biotech ETF  declined 18% in the past six months, and money continues to flow out of the sector. While several biotechs managed to IPO in September and October , it's not all roses. ADC Therapeutics pulled its plans to list citing market...

Market volatility is increasing and that's resulting in some interesting opportunities investors can consider. There's no telling what stocks will pop or drop the most from here; however, it's clear from our most recent research that investors are increasingly focusing on defensive stocks, rat...